# reload+after+2024-01-20 07:46:18.126983
address1§121 South Orange Avenue
address2§Suite 1500
city§Orlando
state§FL
zip§32801
country§United States
phone§407 377 6695
website§https://nutriband.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Serguei  Melnik', 'age': 49, 'title': 'Founder, President, Company Secretary & Executive Chairman of the Board', 'yearBorn': 1974, 'fiscalYear': 2023, 'totalPay': 200000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Gareth  Sheridan', 'age': 33, 'title': 'Founder, CEO & Director', 'yearBorn': 1990, 'fiscalYear': 2023, 'totalPay': 200000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Gerald  Goodman', 'age': 75, 'title': 'CFO & Chief Accounting Officer', 'yearBorn': 1948, 'fiscalYear': 2023, 'totalPay': 160000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Alan  Smith Ph.D.', 'age': 57, 'title': 'COO & President of 4P Therapeutics', 'yearBorn': 1966, 'fiscalYear': 2023, 'totalPay': 179000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Patrick  Ryan', 'age': 37, 'title': 'Chief Technical Officer', 'yearBorn': 1986, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jeffrey  Patrick Pharm.D.', 'age': 53, 'title': 'Chief Scientific Officer', 'yearBorn': 1970, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 2345}, {'maxAge': 1, 'name': 'Mr. Tyler  Overk', 'age': 39, 'title': 'President of Active Intelligence', 'yearBorn': 1984, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
beta§0.29
currency§USD
exchange§NCM
quoteType§EQUITY
shortName§Nutriband Inc. Warrant
longName§Nutriband Inc.
firstTradeDateEpochUtc§1633095000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§e5d40945-7de6-3229-9984-46ccf6e50879
gmtOffSetMilliseconds§-18000000
recommendationKey§none
quickRatio§1.999
grossMargins§0.38801998
ebitdaMargins§-2.2168
trailingPegRatio§None
